7月17日，科伦博泰生物盘中下跌3.25%，报501.5港元，成交额1.92亿港元。公司于7月15日公布核心产品TROP2 ADC芦康沙妥珠单抗联合帕博利珠单抗一线治疗PD-L1阴性NSCLC的III期研究达主要终点，当日股价大涨逾11%，此后连续两个交易日出现利好兑现后的获利回吐。
今日生物科技板块整体大幅走弱，康方生物跌8.5%、三生制药跌6.92%、荣昌生物跌6.53%、信达生物跌2.34%、百济神州跌2.1%，板块系统性抛压进一步加剧个股回调。高盛此前维持公司"买入"评级，但短期技术面承压叠加板块情绪偏弱，股价延续整理走势。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.